Skip to main content

Table 4 The clinicopathological analyses of BC-1514 (C15), BC-1514 (W12), CD1d, and PJA2. Median (average, IQR), * p <  0.05

From: CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature

Parameter   Cases (percentage) BC-1514 (C15) P value BC-1514 (W12) P value CD1d P value PJA2 P value
Age
    < 55 115 (39.1) 180 (160.7, 90–200) 0.903 200 (212.4, 200–300) 0.245 90 (98.2, 60–180) 0.182 180 (157.3, 90–200) 0.956
    ≥ 55 179 (60.9) 180 (162.5, 100–200)   200 (225.7, 200–300)   95 (113.8, 60–180)   180 (155.5, 90–200)  
pT
   I-II 281 (95.6) 180 (161.1, 90–200) 0.368 200 (218.2, 200–300) 0.015* 90 (108.1, 60–180) 0.413 180 (155.9, 90–200) 0.445
   III-IV 13 (4.4) 200 (177.5, 100–300)   300 (266.7, 200–300)   90 (100.0, 10–180)   200 (163.8, 100–200)  
pN
   pN0 192 (65.3) 180 (163.9, 90–200) 0.709 200 (221.6, 200–300) 0.979 90 (109.8, 70–190) 0.466 180 (157.3, 90–200) 0.99
   pN1 or above 102 (34.7) 180 (157.9, 95–200)   200 (218.9, 200–300)   90 (103.9, 40–180)   180 (154.1, 90–200)  
Distant metastasis
   M0 289 (98.3) 180 (160.5, 90–200) 0.121 200 (219.4, 200–300) 0.09 90 (108.1, 60–180) 0.696 180 (155.8, 90–200) 0.222
   M1 5 (1.7) 250 (215.0, 105–300)   300 (266.7, 200–300)   90 (92.0, 45–135)   200 (180.0, 150–200)  
pStage
   I-II 247 (84.0) 180 (161.5, 90–200) 0.525 200 (220.1, 200–300) 0.448 90 (107.2, 60–180) 0.868 180 (155.3, 90–200) 0.416
   III-IV 47 (16.0) 200 (162.9, 100–200)   200 (222.5, 200–300)   90 (110.7, 50–190)   200 (161.0, 100–200)  
Histological grade
   1 or 2 230 (78.2) 180 (158.7, 90–200) 0.176 200 (214.1, 200–300) 0.009* 90 (107.4, 60–180) 0.832 180 (158.2, 95–200) 0.498
   3 64 (21.8) 200 (172.6, 100–200)   200 (242.4, 200–300)   95 (109.2, 60–180)   180 (149.1, 90–200)  
Lymphatic vessel invasion
   absent 128 (43.5) 180 (156.1, 90–200) 0.105 200 (218.8, 200–300) 0.782 90 (110.8, 70–190) 0.524 180 (156.4, 90–200) 0.69
   present 166 (56.5) 200 (166.3, 100–200)   200 (221.8, 200–300)   90 (105.4, 50–180)   180 (156.1, 100–200)  
Blood vessel invasion
   absent 243 (82.7) 180 (163.4, 100–200) 0.57 200 (220.4, 200–300) 0.895 90 (108.4, 60–180) 0.836 180 (157.5, 90–200) 0.543
   present 51 (17.3) 180 (154.3, 90–200)   200 (220.9, 200–300)   90 (104.7, 55–145)   180 (150.0, 100–200)  
ER
   negative 48 (16.3) 200 (157.4, 90–200) 0.97 200 (241.7, 200–300) 0.066 95 (121.7, 90–180) 0.127 200 (165.9, 95–200) 0.226
   positive 246 (83.7) 180 (162.5, 100–200)   200 (217.1, 200–300)   90 (104.9, 60–180)   180 (154.3, 90–200)  
PgR
   negative 96 (32.7) 180 (167.2, 90–200) 0.605 200 (229.5, 200–300) 0.208 90 (110.9, 60–180) 0.632 200 (164.4, 97.5–200) 0.105
   positive 198 (67.3) 180 (159.5, 100–200)   200 (216.7, 200–300)   90 (106.3, 60–190)   180 (152.4, 90–200)  
HER2
   negative 247 (85.2) 180 (160.1, 90–200) 0.161 200 (216.8, 200–300) 0.043* 90 (108.2, 65–190) 0.471 180 (154.4, 90–200) 0.207
   positive 43 (14.8) 200 (176.0, 100–200)   300 (247.6, 200–300)   92.5 (108.3, 40–180)   180 (162.4, 95–200)  
Ki-67
    < 14 68 (23.1) 160 (136.8, 90–200) 0.010* 200 (196.7, 180–250) 0.011* 90 (91.7, 55–92.5) 0.036* 180 (150.8, 90–200) 0.603
    ≥ 14 205 (69.7) 180 (158.9, 95–200)   200 (225.1, 200–300)   95 (112.8, 60–190)   180 (159.5, 90–200)  
Triple negative
   no 263 (89.5) 180 (164.4, 100–200) 0.095 200 (219.4, 200–300) 0.434 90 (106.3, 60–180) 0.106 180 (154.9, 90–200) 0.199
   yes 31 (10.5) 120 (135.8, 70–200)   200 (231.2, 200–300)   97.5 (121.5, 90–190)   200 (167.8, 90–200)